EDIT vs SANA
EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation. SANA: Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology, and autoimmune conditions.
Side-by-side fundamentals
| Metric | EDIT | SANA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.78 | $3.12 | |
| Market cap as of 2026-07-23 | $421M | $868M | |
| PEG as of 2026-07-23 | n/a | -0.55 | |
| Net margin as of 2026-07-23 | -281.6% | n/a | |
| Operating margin as of 2026-07-23 | -281.3% | n/a | |
| ROE as of 2026-07-23 | -677.4% | -161.9% | SANA higher |
| ROA as of 2026-07-23 | -58.3% | -61.0% | EDIT higher |
| Debt / equity as of 2026-07-23 | 12.40 | 0.00 | SANA lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.1% | n/a | |
| Beta as of 2026-07-23 | 2.08 | 2.12 | |
| 1-year return as of 2026-07-22 close | -8.3% | -28.8% | EDIT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.